^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CEBPA (CCAAT Enhancer Binding Protein Alpha)

    i
    Other names: CEBPA, CCAAT Enhancer Binding Protein Alpha, CCAAT/Enhancer Binding Protein (C/EBP), Alpha, CCAAT/Enhancer-Binding Protein Alpha, CEBP, CCAAT/Enhancer Binding Protein Alpha, C/EBP-Alpha, C/EBP Alpha
    8d
    Synergistic adverse prognosis of CEBPA and NRAS co-mutation in acute myeloid leukemia: a retrospective cohort study. (PubMed, Front Cell Dev Biol)
    The NRAS and CEBPA co-mutation defines a distinct molecular subtype with independently poor prognosis in AML. Routine NRAS mutation screening in patients with CEBPA-mutated AML is warranted to refine risk stratification, particularly for identifying this high-risk subgroup, which may benefit from more intensive or novel therapeutic approaches.
    Retrospective data • Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NRAS mutation
    10d
    Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. (PubMed, Cell Death Dis)
    The adipocyte-like phenotype in vivo was sustained through one-month observation period following induction drug withdrawal. This study establishes a plasticity-oriented "convert-instead-of-kill" strategy for EMT-high PDAC, suggesting a potential for future studies to investigate rational combinations (e.g., transdifferentiation therapy combined with targeted or immunotherapy) to exploit lineage conversion.
    Journal • IO biomarker
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • FABP4 (Fatty Acid Binding Protein 4)
    11d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    15d
    Targeting β2-adrenergic receptor reduces UV-induced cutaneous damage and inflammation in a murine model. (PubMed, J Photochem Photobiol)
    Collectively, these gene regulatory alterations were associated with a substantial reduction in innate immune, inflammatory, and mesenchymal tissue differentiation responses to the UV radiation in the KO skin. These data identify β2-AR as a critical neurobiological pathway involved in UV-induced skin damage and inflammation and support that β2-AR blockade might be useful for preventing UV-related skin lesions and sequelae (e.g., cancers).
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    17d
    Functional louts leaf extracellular vesicles for targeted delivery of curcumin through PPAR against obesity. (PubMed, Colloids Surf B Biointerfaces)
    In addition, adipo-8-LEVs-cur did not cause any damage to other organs. These results suggest that the adipo-8-LEVs-cur delivery system provides an idea for obesity treatment targeting adipocytes, which is of practical significance for anti-obesity research.
    Journal
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha) • FASN (Fatty acid synthase) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    17d
    Glyphosate-Induced Metabolic and Immune Modulation in Hepatoma Cells: Identification of Key Genes as Diagnostic and Therapeutic Targets Using an In Silico Systems Biology Approach. (PubMed, J Xenobiot)
    Notably, all hub genes demonstrated strong diagnostic performance, highlighting their potential as sensitive biomarkers of glyphosate exposure. Collectively, this study provides comprehensive insights into gene expression changes associated with glyphosate exposure in hepatoma cells, linking them to hepatic metabolic dysregulation and immune modulation and suggesting a panel of hub genes with potential diagnostic and therapeutic significance.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • CD36 (thrombospondin receptor) • ALDOA (Aldolase Fructose-Bisphosphate A) • ATF3 (Activating Transcription Factor 3) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • PGK1 (Phosphoglycerate Kinase 1) • PNPLA3 (Patatin Like Phospholipase Domain Containing 3) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    22d
    B-cell precursor acute lymphoblastic leukaemia with IGH::CEBP rearrangement: what have we learnt over the years? (PubMed, Haematologica)
    Not available.
    Journal
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    22d
    Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. (PubMed, J Cachexia Sarcopenia Muscle)
    Our work highlights deficient adipose anabolism as a driver of reduced lipid content in 3T3-L1 adipocytes treated with PDAC conditioned media and PDAC mice. The small molecule KH-3, which disrupts HuR binding, restored adipose anabolism in PDAC mice. This highlights HuR as a potentially targetable regulatory node for adipose anabolism in cancer cachexia.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PDX1 (Pancreatic And Duodenal Homeobox 1)
    |
    KRAS G12D • KRAS G12
    22d
    Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov)
    P2, N=77, Recruiting, The First Affiliated Hospital of Soochow University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    NPM1 (Nucleophosmin 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation
    |
    azacitidine • decitabine
    25d
    DNA Methylation Stochasticity is Linked to Transcriptional Variability and Convergent Epigenetic Disruption Across Genetic Subtypes of Acute Myeloid Leukemia. (PubMed, Cancer Res)
    Finally, the hypomethylating drug decitabine led to reduction of DNA methylation entropy specifically in IDH2-mutant AML cells. Overall, this approach identified a convergent program of epigenetic dysregulation in leukemia, clarifying the contribution of specific genetic mutations to stochastic disruption of the epigenetic and transcriptional landscapes of AML.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    IDH2 mutation • TMB-L
    |
    decitabine
    28d
    DNMT3B Controls Enhancer-Linked Chromatin and Cell Cycle Networks in Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
    DNMT3B functions as a context-dependent epigenetic regulator linking enhancer-associated chromatin organization with proliferative control and apoptotic resistance in AML. DNMT3B-directed epigenetic perturbation remodels cis-regulatory circuitry and is associated with increased venetoclax responsiveness, supporting DNMT3B-governed networks as a candidate co-targeting axis in high-risk AML.
    Journal • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • DNMT3B (DNA Methyltransferase 3 Beta)
    |
    NPM1 mutation
    |
    Venclexta (venetoclax)
    1m
    Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML (clinicaltrials.gov)
    P1/2, N=29, Recruiting, The First Affiliated Hospital of Soochow University
    New P1/2 trial
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine